174 related articles for article (PubMed ID: 34407044)
21. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer.
Orlando L; Cardillo A; Rocca A; Balduzzi A; Ghisini R; Peruzzotti G; Goldhirsch A; D'Alessandro C; Cinieri S; Preda L; Colleoni M
Anticancer Drugs; 2006 Sep; 17(8):961-7. PubMed ID: 16940806
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial.
He M; Liu J; Wang Z; Ma F; Wang J; Zhang P; Li Q; Yuan P; Luo Y; Fan Y; Mo H; Lan B; Li Q; Xu B
Breast; 2023 Dec; 72():103581. PubMed ID: 37742492
[TBL] [Abstract][Full Text] [Related]
23. Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients.
Geng R; Wang G; Qiu L; Liu B; Yang F; Zhang J; Miao Y
Medicine (Baltimore); 2020 Dec; 99(51):e23719. PubMed ID: 33371122
[TBL] [Abstract][Full Text] [Related]
24. Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial.
Montagna E; Bagnardi V; Cancello G; Sangalli C; Pagan E; Iorfida M; Mazza M; Mazzarol G; Dellapasqua S; Munzone E; Goldhirsch A; Colleoni M
Breast Care (Basel); 2018 Jul; 13(3):177-181. PubMed ID: 30069178
[TBL] [Abstract][Full Text] [Related]
25. Metronomic oral chemotherapy with old agents in patients with heavily treated metastatic breast cancer.
Mutlu H; Musri FY; Artaç M; Kargi A; Özdogan M; Bozcuk H
J Cancer Res Ther; 2015; 11(2):287-90. PubMed ID: 26148586
[TBL] [Abstract][Full Text] [Related]
26. Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study.
Steger GG; Dominguez A; Dobrovolskaya N; Giotta F; Tubiana-Mathieu N; Pecherstorfer M; Ardizzoia A; Blasinska-Morawiec M; Espinosa E; Villanova G
Clin Breast Cancer; 2018 Feb; 18(1):e41-e47. PubMed ID: 28666812
[TBL] [Abstract][Full Text] [Related]
27. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
Chen XL; Du F; Hong RX; Wang JY; Luo Y; Li Q; Fan Y; Xu BH
Chin J Cancer; 2016 Apr; 35():39. PubMed ID: 27112139
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Toxicity of Metronomic Chemotherapy in Metastatic Breast Cancer: Egyptian Experience.
Hussein MM; Gaafar RM; Abdel-Warith AM; Ahmed WA; Allahloubi NMA; Salem SE; Abdel-Salam IM
Clin Breast Cancer; 2017 Dec; 17(8):618-628. PubMed ID: 28625341
[TBL] [Abstract][Full Text] [Related]
29. Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients.
Torres A; Ramdial JL; Aguirre LE; Mahtani R; Vogel CL
Breast Cancer Res Treat; 2019 Jul; 176(2):253-260. PubMed ID: 30900138
[TBL] [Abstract][Full Text] [Related]
30. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.
Cazzaniga ME; Vallini I; Montagna E; Amoroso D; Berardi R; Butera A; Cagossi K; Cavanna L; Ciccarese M; Cinieri S; Cretella E; De Conciliis E; Febbraro A; Ferraù F; Ferzi A; Baldelli A; Fontana A; Gambaro AR; Garrone O; Gebbia V; Generali D; Gianni L; Giovanardi F; Grassadonia A; Leonardi V; Marchetti P; Sarti S; Musolino A; Nicolini M; Putzu C; Riccardi F; Santini D; Saracchini S; Sarobba MG; Schintu MG; Scognamiglio G; Spadaro P; Taverniti C; Toniolo D; Tralongo P; Turletti A; Valenza R; Valerio MR; Vici P; Di Mauro P; Cogliati V; Capici S; Clivio L; Torri V;
Breast Cancer Res Treat; 2021 Dec; 190(3):415-424. PubMed ID: 34546500
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
32. All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer.
Tawfik H; Rostom Y; Elghazaly H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):913-9. PubMed ID: 23344713
[TBL] [Abstract][Full Text] [Related]
33. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
Welt A; von Minckwitz G; Oberhoff C; Borquez D; Schleucher R; Loibl S; Harstrick A; Kaufmann M; Seeber S; Vanhoefer U
Ann Oncol; 2005 Jan; 16(1):64-9. PubMed ID: 15598940
[TBL] [Abstract][Full Text] [Related]
34. Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study.
Tanaka M; Takamatsu Y; Anan K; Ohno S; Nishimura R; Yamamoto Y; Masuda N; Mitsuyama S; Tamura K;
Anticancer Drugs; 2010 Apr; 21(4):453-8. PubMed ID: 20075712
[TBL] [Abstract][Full Text] [Related]
35. Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer.
Brems-Eskildsen AS; Linnet S; Danø H; Luczak A; Vestlev PM; Jakobsen EH; Neimann J; Jensen CB; Dongsgaard T; Langkjer ST
Acta Oncol; 2021 Feb; 60(2):157-164. PubMed ID: 33259244
[TBL] [Abstract][Full Text] [Related]
36. Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real-world data analyses and experience of one center.
Lu Q; Lee K; Xu F; Xia W; Zheng Q; Hong R; Jiang K; Zhai Q; Li Y; Shi Y; Yuan Z; Wang S
Cancer Commun (Lond); 2020 May; 40(5):222-233. PubMed ID: 32390331
[TBL] [Abstract][Full Text] [Related]
37. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
[TBL] [Abstract][Full Text] [Related]
38. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer.
Nolè F; Crivellari D; Mattioli R; Pinotti G; Foa P; Verri E; Fougeray R; Brandely M; Goldhirsch A
Cancer Chemother Pharmacol; 2009 Sep; 64(4):673-80. PubMed ID: 19184601
[TBL] [Abstract][Full Text] [Related]
40. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer.
De Iuliis F; Salerno G; Taglieri L; Lanza R; Scarpa S
Tumori; 2015; 101(1):30-5. PubMed ID: 25702645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
